I actually find this fascinating as it puts a dollar figure on it.
It’s similar to the FDA priority voucher market. If you get a drug approved by the FDA for a neglected disease, you get a transferable voucher that gets you a priority FDA review for whatever drug you use it for. It might accelerate approval by 3-6 months.
What’s that worth? Well the vouchers have sold for $100-250M lately.
> Well the vouchers have sold for $100-250M lately.
Not to dismiss what you are saying, but "I can get regulatory approval for my drug faster" seems like it got far more valuable in the past, I dunno, 20-21 months or so.
The COVID vaccines took priority over everything (rightly so). But that meant that the FDA had less time to approve anything else, so priority still became more valuable.
I didn't mean the voucher would let you cut in front of the vaccine. The vaccine work didn't occupy 100% of the FDA. Let's say it ate up 75%. Well, the vouchers probably worked on the other 25%. And because there is a lot less available time, the vouchers are more valuable.
I mean, imagine they have space for only one non-COVID review in 2020. Can you imagine how much that would be worth?
It’s similar to the FDA priority voucher market. If you get a drug approved by the FDA for a neglected disease, you get a transferable voucher that gets you a priority FDA review for whatever drug you use it for. It might accelerate approval by 3-6 months.
What’s that worth? Well the vouchers have sold for $100-250M lately.
https://www.fiercepharma.com/pharma/sanofi-nets-valuable-fda...